Michael Lawrence, MD
Allergy · Brockton, MANPI 1477506541
Payments from drug & device makers
Across 541 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Genentech USA, Inc.$2K
- GSK$1K
- Novartis$1K
- Regeneron Healthcare Solutions, Inc.$480
- Pfizer$465
- plus $3K from 32 others
What the payments were for
- Consulting fees$160%
- Food & beverage$10,36498%
- Education$1632%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 103 | $2,268 |
| Genentech USA, Inc. | 92 | $1,627 |
| GSK | 85 | $1,430 |
| Novartis | 68 | $1,175 |
| Regeneron Healthcare Solutions, Inc. | 21 | $480 |
| Pfizer | 24 | $465 |
| Grifols USA, LLC | 24 | $444 |
| Boehringer Ingelheim | 15 | $301 |
| Octapharma USA, Inc. | 12 | $275 |
| Pharming Healthcare, Inc. | 11 | $264 |
| Amgen | 7 | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $208 |
| Sanofi | 10 | $178 |
| Teva Pharmaceuticals USA, Inc. | 9 | $145 |
| LEO Pharma Inc. | 5 | $134 |
| Kaleo, Inc. | 7 | $131 |
| Optinose US, Inc. | 5 | $115 |
| AbbVie | 4 | $108 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $73 |
| GC Biopharma USA, Inc. | 2 | $53 |
| Covis Pharma GmbH | 2 | $33 |
| Circassia Inc. | 2 | $32 |
| Galderma Laboratories, L.p. | 2 | $31 |
| Shire North American Group Inc | 2 | $29 |
| Mylan Specialty L.p. | 2 | $29 |
| CSL Behring | 1 | $28 |
| Organon | 1 | $27 |
| Greer Laboratories, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $25 |
| Cycle Pharmaceuticals Inc | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| ADMA Biomanufacturing LLC | 2 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Alk-abello, Inc | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
| Mylan Pharmaceuticals Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$326
- FASENRA$220
- AIRSUPRA$118
- TUDORZA PRESSAIR$118
How this compares
$10,544 in reported general payments places this provider in the 85th percentile of 21 allergy providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 24 | $90,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $83,615 |
| XolairOmalizumab | 33 | $75,714 |
| Breo ElliptaFluticasone/Vilanterol | 114 | $66,348 |
| NucalaMepolizumab | 11 | $37,567 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $20,759 |
| Spiriva RespimatTiotropium Bromide | 16 | $13,786 |
| DuleraMometasone/Formoterol | 15 | $12,634 |
| Arnuity ElliptaFluticasone Furoate | 34 | $9,555 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $9,154 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 72 | $8,111 |
| Wixela InhubFluticasone Propion/Salmeterol | 38 | $6,718 |
| Qvar RedihalerBeclomethasone Dipropionate | 25 | $5,865 |
| Azelastine Hcl | 148 | $5,103 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 166 | $4,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta | $1,430 | $197,086229 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,268 | $29,91344 claims |
| Boehringer IngelheimSpiriva Respimat | $301 | $13,78616 claims |
| MerckDulera | $19 | $12,63415 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $145 | $5,86525 claims |
| Hikma Pharmaceuticals USAEpinephrine | $16 | $3,66822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 21 allergy providers in Massachusetts.
Other allergy in Brockton
- Mark ClausBrockton$13K
- Ralph CahalyMilford$30K
- John SaryanBurlington$15K
- Margaret Vallen MashikianSouth Weymouth$9K
- Priyal AminWestford$3K
- Li LiangChelmsford$2K
- Bryan StoneLawrence$2K
- Fuad MudawwarFlorence$2K
- Frank TwarogConcord$1K
- Stuart RheinFramingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.